Over the past decade, circular RNAs (circRNAs) have emerged as a large class of primarily
non-coding RNA molecules, many of which have key roles in cancer development and …

Summary The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA)
using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic …

Mass-spectrometry-based proteomic data on human tumors—combined with corresponding
multi-omics data—present opportunities for systematic and pan-cancer proteogenomic …

To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic
opportunities, we performed comprehensive proteogenomic characterization of 110 tumors …

Genomic analyses in cancer have been enormously impactful, leading to the identification of
driver mutations and development of targeted therapies. But the functions of the vast majority …

Proteomics has become an important field in molecular sciences, as it provides valuable
information on the identity, expression levels, and modification of proteins. For example …

We report a comprehensive proteogenomics analysis, including whole-genome sequencing,
RNA sequencing, and proteomics and phosphoproteomics profiling, of 218 tumors across 7 …

The paradigm of cancer-targeted therapies has focused largely on inhibition of critical
pathways in cancer. Conversely, conditional activation of signaling pathways as a new …